Last Week’s Promising News
This content is for members
Halozyme Therapeutics (HALO)
Halozyme: Helping Immunotherapy Products. Abeona: An Attractive Newcomer to the Stock Market
This content is for members
Some Small Outperforming Biotech Firms
This content is for members
Two Large Pharma Agreements with Halozyme in One Day. HALO Rallied
This content is for members
Halozyme’s Approved Drug, Promising News and Ongoing Pancreatic Cancer Trials
This content is for members
Prohost Letter #411
This content is for members
Prohost Letter #410
This content is for members
Halozyme’s PEGPH20 Trial Results Are Worth Appreciating Not Doubting
Extremely important, not just exciting, were the results of Halozyme Therapeutics’s (HALO) Phase 2 randomized, multi-center clinical trial of its PEGPH20 in …
Prohost Letter #394 Part 2
This content is for members
Halozyme: Reading the News While Keeping Our Focus on the Promises
This content is for members
Halozyme: A Lucrative Agreement Signed with Eli Lilly. Gossip About Acquisition
This content is for members
Halozyme PEGPH20 Improves the Efficacy of Halavan in Triple Negative Breast Cancer
Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …
Halozyme: Improving the Treatment of Triple Negative Breast Cancer
This content is for members
Halozyme Has Good News and Array Too
This content is for members
Prohost Letter #386
This content is for members
Prohost Letter #385
This content is for members